Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Kumar SS, Devasagayam TP, Bhushan B, Verma NC (2001) Scavenging of reactive oxygen species by chlorophyllin: an ESR study
Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease
Readers - what are your thoughts on GLP-1 receptor agonists for Alzheimers disease
Foundation Zoomer : broad-spectrum baseline markers including liver enzymes, inflammatory markers, and nutrient status that reflect overall Phase II capacity Cellular Zoomer : measures mitochondrial function, oxidative stress markers, and glutathione status, all of which directly impact GST conjugation and energy-dependent pathways Toxin Zoomer : detects environmental toxins (heavy metals, plasticizers, pesticides) and their metabolites, showing what the body is being asked to conjugate Mosaic OAT (Organic Acids Test) : hippuric acid (glycine conjugation of benzoic acid), pyroglutamic acid (glutathione depletion marker), methylation markers, and mitochondrial intermediates Hepatic Detox Profile : directly measures Phase I and Phase II enzyme activity using challenge substrates (caffeine for CYP1A2/NAT2/xanthine oxidase, aspirin for glycine conjugation, acetaminophen for glucuronidation/sulfation/GST conjugation) Hepatic Function Panel : liver enzymes (ALT, AST, GGT, ALP, bilirubin) that reflect hepatocyte health and biliary function Nutrient Zoomer : measures B12, folate, B6, magnesium, zinc, selenium, cysteine, glutathione, and other cofactors critical for every conjugation pathway Methylation Genetics : MTHFR, COMT, CBS, MTR, MTRR, BHMT, and related SNPs that directly affect methylation conjugation and transsulfuration to glutathione A combination of the Hepatic Detox Profile (functional Phase I/II capacity), the OAT (downstream organic acid metabolites), and the Nutrient Zoomer (cofactor status) provides the most comprehensive picture of conjugation function
Quantifying the impact from the diabetic population requires a number of additional assumptions: Prevalence of diabetes in the population The proportion of the population eligible for the drug as a diabetes treatment
